Kiniksa Pharmaceuticals Files 8-K on Financials
Ticker: KNSA · Form: 8-K · Filed: 2025-01-13T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, corporate-actions
TL;DR
Kiniksa dropped an 8-K on Jan 13th covering financials - check it out.
AI Summary
Kiniksa Pharmaceuticals International, plc filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 23 Old Bond Street, Floor 3, London, W1S 4PZ, England. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name on February 5, 2018.
Why It Matters
This 8-K filing provides investors with an update on Kiniksa Pharmaceuticals' financial performance and condition, which is crucial for assessing the company's stability and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not appear to contain any significant new risks or material adverse events.
Key Players & Entities
- Kiniksa Pharmaceuticals International, plc (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- 23 Old Bond Street, Floor 3, London, W1S 4PZ, England (location) — Principal executive offices
- Kiniksa Pharmaceuticals, Ltd. (company) — Former company name
- February 5, 2018 (date) — Date of name change
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported is dated January 13, 2025.
What is the principal executive office address for Kiniksa Pharmaceuticals International, plc?
The principal executive offices are located at 23 Old Bond Street, Floor 3, London, W1S 4PZ, England.
Has Kiniksa Pharmaceuticals International, plc always been known by this name?
No, the company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name on February 5, 2018.
What is the SIC code for Kiniksa Pharmaceuticals International, plc?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-01-13 07:34:36
Key Financial Figures
- $0.000273235 — h registered Class A Ordinary Shares $0.000273235 nominal value KNSA The Nasdaq Stock
- $121.9 million — at (i) ARCALYST net product revenue was $121.9 million and $416.4 million for the fourth quart
- $416.4 million — product revenue was $121.9 million and $416.4 million for the fourth quarter and full year 20
- $243.6 million — and (ii) as of December 31, 2024 it had $243.6 million of cash, cash equivalents and short-ter
Filing Documents
- tm252986d1_8k.htm (8-K) — 25KB
- tm252986d1_ex99-1.htm (EX-99.1) — 34KB
- tm252986d1_ex99-1img001.jpg (GRAPHIC) — 17KB
- 0001104659-25-002858.txt ( ) — 257KB
- knsa-20250113.xsd (EX-101.SCH) — 3KB
- knsa-20250113_lab.xml (EX-101.LAB) — 33KB
- knsa-20250113_pre.xml (EX-101.PRE) — 22KB
- tm252986d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On January 13, 2025, Kiniksa Pharmaceuticals International, plc issued a press release announcing, among other things, that (i) ARCALYST net product revenue was $121.9 million and $416.4 million for the fourth quarter and full year 2024, respectively (unaudited) and (ii) as of December 31, 2024 it had $243.6 million of cash, cash equivalents and short-term investments (unaudited). A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Kiniksa Pharmaceuticals International, plc, dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC Date: January 13, 2025 By: /s/ Madelyn Zeylikman Madelyn Zeylikman Senior Vice President, General Counsel and Secretary